<DOC>
	<DOCNO>NCT00990080</DOCNO>
	<brief_summary>To demonstrate safety immunogenicity two mixed primary immunization schedule : Pediacel® 2 4 month age follow one dose Infanrix™ IPV/Hib 6 month age ; , Infanrix™ IPV/Hib 2 month age , follow Pediacel® 4 6 month age .</brief_summary>
	<brief_title>Interchangeability Infanrix™ IPV/Hib Pediacel® 2,4 &amp; 6 Months Age</brief_title>
	<detailed_description>Immunogenicity evaluate use follow : Serological outcome measure assess day 0 ( visit 1 ) 28-42 day 3rd dose primary series group : - Seroprotection rate antibody PRP ( anti-PRP ) , define percentage subject antibody concentration ≥ 0.15 µg/ml ≥ 1.0 µg/ml . - Geometric mean concentration ( GMC ) antibodies PT , FHA , PRN , FIM . - Anti-pertussis antibody concentration ≥4-fold rise ( post-Dose 3/pre-Dose 1 ) . Safety evaluate use follow : - Occurrence , time onset , number day occurrence , severity seriousness solicit injection site reaction ( tenderness , erythema , swell ) systemic symptom ( fever , vomit , cry abnormal , drowsiness , appetite decrease , irritability ) within 8 day ( Day 0 - Day 7 ) vaccination across vaccination . - Occurrence , nature , time onset , duration , severity , relationship vaccination unsolicited adverse event ( AE ) occur within 31 day ( Day 0 -Day 30 ) vaccination . - Occurrence , nature , time onset , duration , relationship vaccination serious adverse event ( SAE ) entire study period group .</detailed_description>
	<criteria>1 . Infants age 6 wks ( 42 day ) 2 month ( 1 day turn 3 month ) inclusive day inclusion . 2 . Born full term pregnancy ( define ≥37 week , 0 day ) . 3 . Informed consent form sign parent ( ) legally authorize representative . 4 . Able attend schedule visit comply study procedure . 5 . Parent legally authorize representative access telephone . 6 . Parent legally authorize representative able read write English French . 1 . Participation another clinical trial 4 week precede first trial vaccination . 2 . Planned participation another clinical trial present trial period . 3 . Personal history congenital acquire immunodeficiency , immunosuppressive therapy longterm systemic corticosteroid therapy . 4 . Known suspected systemic hypersensitivity vaccine component history lifethreatening reaction vaccine contain substance trial vaccine ( ) . 5 . Chronic illness could interfere trial conduct completion . 6 . Received blood bloodderived product since birth . 7 . Any vaccination precede first trial vaccination , except vaccination recommend part infant schedule . 8 . Previous vaccination acellular pertussis ( DTaP ) whole cell pertussisDTwP ) base combination vaccine , Haemophilus influenzae type b Hib ) conjugate , poliovirus vaccine . 9 . Coagulation disorder contraindicate intramuscular vaccination . 10 . Clinically significant finding review system ( determined investigator subinvestigator sufficient exclusion ) . 11 . Developmental delay neurological disorder . 12 . Any condition , opinion investigator , would interfere evaluation vaccine pose health risk subject . 13 . History Hib , diphtheria , tetanus , pertussis poliovirus disease .</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>3 Months</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>